Medication adherence after myocardial infarction remains low. Pharmacy claims have typically been used to measure medication adherence, but electronic pill bottles may offer additional information.
The main objectives of this study were to compare the association of adherence measured by prescription claims and remote monitoring technologies with cardiovascular events.
This study was a secondary analysis of a remote monitoring intervention to increase medication adherence in myocardial infarction patients.
In total, 682 myocardial infarction patients were randomized to the intervention group with both medical and pharmacy benefits.
Pharmacy claims adherence was measured using proportion of days covered (PDC) and GlowCap adherence (GC) was measured as the proportion of days the pill bottle was opened. We compared the association of PDC and GC adherence for statins with time to first vascular readmission or death and assessed model fit using Akaike information criterion and Bayesian information criterion and the likelihood ratio test.
Higher PDC was significantly associated with a lower hazard rate for vascular readmissions or death (hazard ratio=0.435; P=0.009). There was also an association between GC adherence and vascular readmissions or death (hazard ratio=0.313; P≤0.001). Adding the GC adherence variable to the model using only PDC improved the model fit (likelihood ratio test, P=0.001), as well as vice versa (P=0.050).
Pharmacy claims data provide useful but not complete data for medication adherence monitoring. New wireless technologies have the potential to provide additional data about clinical outcomes.
*Department of Medicine, Perelman School of Medicine
†Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania
‡Penn Medicine Center for Health Care Innovation
§Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA
∥Department of Population Health, Division of Biostatistics, NYU School of Medicine, New York, NY
This study was funded with a grant from the Center for Medicare & Medicaid Innovation, Health Care Innovation Award 1C1CMS331009.
The results of this study were presented at AcademyHealth, June 6, 2017, New Orleans, LA.
D.A.A. and K.G.V. are principals at the behavioral economics consulting firm VAL Health. A.B.T. serves on the scientific advisory board of VAL Health. K.G.V. has received consulting income from CVS Caremark and research funding from Humana, CVS Caremark, Discovery (South Africa), Hawaii Medical Services Association, Weight Watchers, and Merck. The remaining authors declare no conflict of interest.
Reprints: Shivan J. Mehta, MD, MBA, MSHP, Perelman School of Medicine, University of Pennsylvania, 14-174 South Tower, PCAM, 3400 Civic Center Boulevard, Philadelphia, PA 19104. E-mail: email@example.com.